Avidity Biosciences
About: Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Employees: 391
0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
267% more call options, than puts
Call options by funds: $8.33M | Put options by funds: $2.27M
15% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 72
1.39% more ownership
Funds ownership: 110.98% [Q1] → 112.37% (+1.39%) [Q2]
3% less capital invested
Capital invested by funds: $3.96B [Q1] → $3.85B (-$116M) [Q2]
7% less funds holding
Funds holding: 219 [Q1] → 203 (-16) [Q2]
22% less funds holding in top 10
Funds holding in top 10: 9 [Q1] → 7 (-2) [Q2]
27% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 37
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$54
19%
upside
Avg. target
$68
50%
upside
High target
$96
111%
upside
9 analyst ratings
9 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Yanan Zhu | 65%upside $75 | Overweight Maintained | 8 Aug 2025 |
Barclays Gena Wang | 36%upside $62 | Overweight Maintained | 8 Aug 2025 |
Chardan Capital Keay Nakae | 65%upside $75 | Buy Maintained | 8 Aug 2025 |
Goldman Sachs Corinne Johnson | 21%upside $55 | Buy Reinstated | 10 Jul 2025 |
Cantor Fitzgerald Eric Schmidt | 111%upside $96 | Overweight Reiterated | 27 Jun 2025 |
Financial journalist opinion
Based on 6 articles about RNA published over the past 30 days
Positive
Zacks Investment Research
19 hours ago
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?
Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.
Positive
The Motley Fool
2 weeks ago
Avidity (RNA) Q2 Revenue Jumps 88%
Avidity (RNA) Q2 Revenue Jumps 88%
Neutral
PRNewsWire
2 weeks ago
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights
Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study Planned del-zota BLA submission at year end 2025 for DMD44 on track to be Avidity's first BLA submission On track for three potential BLA submissions over a 12-month period Strong balance sheet and cash runway to mid-2027 enabling global commercial launch readiness; first potential commercial launch in U.S. in 2026 SAN DIEGO , Aug. 7, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today reported financial results for the second quarter ended June 30, 2025 and highlighted recent progress. "Avidity continues to deliver on its leadership in RNA therapeutics as we prepare for three potential BLA submissions in a 12-month period with strong clinical data, regulatory progress, and operational execution," said Sarah Boyce, president and chief executive officer of Avidity.
Positive
Investors Business Daily
2 weeks ago
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal
Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech company.
Positive
Reuters
2 weeks ago
Novartis weighs deal for biotech Avidity Biosciences, FT reports
Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar with the matter
Neutral
PRNewsWire
4 weeks ago
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
-- Topline data readout from HARBOR study anticipated in Q2 2026 -- -- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated to start in H2 2026; on track to potentially be the first globally approved drug for DM1-- -- On track to share updates from ongoing MARINA-OLE™ trial of del-desiran including long-term 4 mg/kg efficacy and safety data in Q4 2025 -- SAN DIEGO , July 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the completion of enrollment in the ongoing global Phase 3 HARBOR™ clinical trial of delpacibart etedesiran (del-desiran) for people living with myotonic dystrophy type 1 (DM1). Topline data from HARBOR, the first global Phase 3 clinical trial in DM1, are anticipated in the second quarter of 2026.
Neutral
PRNewsWire
1 month ago
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
-- On track for planned BLA submission for del-zota at year end 2025 -- SAN DIEGO , July 23, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to delpacibart zotadirsen (del-zota) for the treatment of Duchenne muscular dystrophy (DMD) in people living with mutations amenable to exon 44 skipping (DMD44). Del-zota is currently being assessed in the Phase 2 EXPLORE44 Open-Label Extension (EXPLORE44-OLE™) trial for people living with DMD44 and is the first of multiple AOCs the company is developing for DMD.
Neutral
PRNewsWire
2 months ago
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
-- FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) -- -- Jeffrey M. Statland, M.D.
Neutral
PRNewsWire
2 months ago
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and significant reduction in biomarkers -- -- Data support planned accelerated approval BLA submission in H2 2026 -- -- Data being presented at the 32nd Annual FSHD Society International Research Congress (IRC); Investor and analyst webcast event today, Monday, June 9 at 8:00 a.m. ET -- SAN DIEGO , June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced positive topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE™ program in Facioscapulohumeral Muscular Dystrophy (FSHD).
Neutral
PRNewsWire
2 months ago
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
-- Planning accelerated approval BLA submission in H2 2026, following topline data fromFORTITUDE™ biomarker cohort in Q2 2026 -- -- Initiated global, confirmatory Phase 3 FORWARD ™ study of del-brax 2mg/kg every six weeks -- -- Investor and analyst webcast event today, Monday, June 9, 2025 at 8 a.m. ET -- SAN DIEGO , June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced the accelerated approval regulatory pathway in the United States is open for delpacibart braxlosiran (del-brax) in the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Charts implemented using Lightweight Charts™